ZA895325B - Neutralization of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and the fragments derived therefrom - Google Patents
Neutralization of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and the fragments derived therefromInfo
- Publication number
- ZA895325B ZA895325B ZA895325A ZA895325A ZA895325B ZA 895325 B ZA895325 B ZA 895325B ZA 895325 A ZA895325 A ZA 895325A ZA 895325 A ZA895325 A ZA 895325A ZA 895325 B ZA895325 B ZA 895325B
- Authority
- ZA
- South Africa
- Prior art keywords
- tnf
- neutralization
- vitro
- alpha
- monoclonal antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3823804A DE3823804A1 (en) | 1988-07-14 | 1988-07-14 | NEUTRALIZATION OF THE TOXIC PROPERTIES OF TNF- (ALPHA) IN VITRO AND VIVO BY MONOCLONAL ANTIBODIES AND THE FRAGMENTS DERIVED FROM THEM |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA895325B true ZA895325B (en) | 1991-04-24 |
Family
ID=6358617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA895325A ZA895325B (en) | 1988-07-14 | 1989-07-13 | Neutralization of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and the fragments derived therefrom |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0350690A3 (en) |
JP (1) | JPH02109994A (en) |
DE (1) | DE3823804A1 (en) |
DK (1) | DK346789A (en) |
FI (1) | FI893428A (en) |
ZA (1) | ZA895325B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
DE69231828T3 (en) * | 1991-03-18 | 2008-06-19 | New York University | Specific anti-human tumor necrosis factor monoclonal and chimeric antibodies |
US6193969B1 (en) * | 1993-06-03 | 2001-02-27 | Protherics Inc. | Antibody fragments in therapy |
DE69626829T2 (en) * | 1995-08-04 | 2004-03-18 | Lek Farmacevtska Druzba D.D. | MONOCLONAL ANTIBODIES AGAINST SOLUBLE TNF-ALPHA RECEPTORS P55 AND P75 AND ALSO AGAINST TNF-ALPHA AND ITS ANALOGS |
GB9517538D0 (en) * | 1995-08-26 | 1995-10-25 | Therapeutic Antibodies Inc | Production and therapeutic combinations, of antibodies |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
CA2508375C (en) | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
RU2010107994A (en) * | 2007-08-08 | 2011-09-20 | Эбботт Лэборетриз (Us) | COMPOSITIONS AND METHODS OF CRYSTALLIZING ANTIBODIES |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
MA47362A (en) | 2017-01-30 | 2019-12-04 | Janssen Biotech Inc | ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE PSORIASIC RHEUMATISM |
MA47442A (en) | 2017-02-07 | 2019-12-18 | Janssen Biotech Inc | ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLARTHRITIS |
BR112021023295A2 (en) | 2019-05-23 | 2022-02-08 | Janssen Biotech Inc | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf-alpha |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3631229A1 (en) * | 1986-09-13 | 1988-03-24 | Basf Ag | MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE |
EP0355067A1 (en) * | 1988-08-19 | 1990-02-21 | Celltech Limited | Pharmaceutical products for anti-neoplastic therapy |
-
1988
- 1988-07-14 DE DE3823804A patent/DE3823804A1/en not_active Withdrawn
-
1989
- 1989-06-24 EP EP89111538A patent/EP0350690A3/en not_active Withdrawn
- 1989-07-13 DK DK346789A patent/DK346789A/en not_active Application Discontinuation
- 1989-07-13 ZA ZA895325A patent/ZA895325B/en unknown
- 1989-07-14 JP JP1180674A patent/JPH02109994A/en active Pending
- 1989-07-14 FI FI893428A patent/FI893428A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0350690A2 (en) | 1990-01-17 |
DK346789D0 (en) | 1989-07-13 |
EP0350690A3 (en) | 1990-07-04 |
JPH02109994A (en) | 1990-04-23 |
FI893428A (en) | 1990-01-15 |
DK346789A (en) | 1990-01-15 |
FI893428A0 (en) | 1989-07-14 |
DE3823804A1 (en) | 1990-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA895325B (en) | Neutralization of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and the fragments derived therefrom | |
EG19493A (en) | Novel antibodies reactive with human carcinomas | |
IL88145A0 (en) | Monoclonal antibodies against human interleukin-4 and hybridomas producing the same | |
GB8910395D0 (en) | Human monoclonal antibody and hybridoma producing the same | |
OA09658A (en) | Materials and methods for the treatment of foreign tissue | |
AU628288B2 (en) | Cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins | |
HU9200293D0 (en) | Process for the production of monoclonal antibodies and their fragments | |
AU6036690A (en) | Human monoclonal antibodies to hiv-1mn gp 120 | |
EP0438339A3 (en) | Process for obtaining articles having the aspect of natural stones and articles obtained | |
NZ234049A (en) | Peptide epitopes of, and antibodies to htlv-1 | |
AU9053991A (en) | Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization | |
EP0285511A3 (en) | Monoclonal antibodies and their uses | |
GB9102616D0 (en) | Antibodies and their use as drug vectors | |
IL86960A0 (en) | Preparation of human monoclonal antibodies | |
HK87195A (en) | Process for the preparation of sulfated alkanol or alkylphenolox-ethylates with low content of 1,4 dioxane | |
GB8901832D0 (en) | Human monoclonal antibody and its production and use | |
EP0407586A4 (en) | Human monoclonal antibody and process for its preparation | |
ZA907279B (en) | Antibodies and proteins | |
GB9010190D0 (en) | Composition for the treatment of protozoal disease and their use | |
EP0427942A3 (en) | Process for the preparation of s-triazine-sulfenimides and their use | |
MX9203512A (en) | NEUTRALIZATION OF THE IN VITRO AND LIVE TOXIC PROPERTIES OF TNF-ALPHA THROUGH MONOCLONAL ANTIBODIES AND THE FRAGMENTS DERIVED FROM THEM. | |
AU6964891A (en) | Novel monoclonal antibody against human platelets | |
EP0414921A4 (en) | Human monoclonal antibody reactive with pseudomonas aeruginosa, cell which produces the antibody, method of production, and pharmaceutical preparation | |
EP0466262A3 (en) | Process for the preparation of zinc carbocysteinate compositions and their use in hepatopathies | |
IE891095L (en) | Human monoclonal antibodies |